Purpose

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: - Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? - Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Age ≥ 18 years and < 66 years (chemotherapy-based conditioning) or < 61 years (total body irradiation [TBI]-based conditioning) at the time of signing informed consent 2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and institutional requirements. 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Planned MAC regimen as defined per study protocol 5. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age ≥ 18 and ≤ 40 years (≤ 35 preferred). 6. Product planned for infusion is MMUD T-cell replete PBSC allograft 7. HCT-CI < 5. The presence of prior malignancy will not be used to calculate HCT-CI for this trial to allow for the inclusion of patients with secondary or therapy-related AML or MDS. 8. One of the following diagnoses: 1. Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or other acute leukemia in 1st remission or beyond with ≤ 5% marrow blasts and no circulating blasts or evidence of extra-medullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning. 2. Patients with MDS with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% or 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning. 9. Cardiac function: Left ventricular ejection fraction ≥ 45% based on most recent echocardiogram or multi-gated acquisition scan (MUGA) results. 10. Estimated creatinine clearance ≥ 45mL/min calculated by equation. 11. Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin > 50% and forced expiratory volume in first second (FEV1) predicted > 50% based on most recent pulmonary function test (PFT) results 12. Liver function acceptable per local institutional guidelines 13. KPS of ≥ 70% Stratum 2 Recipient Inclusion Criteria: 1. Age ≥18 years at the time of signing informed consent 2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements. 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Planned NMA/RIC regimen per study protocol 5. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age ≥ 18 and ≤ 40 years (≤ 35 preferred). 6. Product planned for infusion is MMUD T-cell replete PBSC allograft 7. One of the following diagnoses: 1. Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with < 5% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning. 2. Patients with MDS with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% or 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning. 3. Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation 4. Higher risk CMML according to CMML-specific prognostic scoring system or high risk MDS/MPN not otherwise specified are eligible, provided there is no evidence of high-grade bone marrow fibrosis or massive splenomegaly at the time of enrollment. 5. Patients with lymphoma with chemosensitive disease at the time of transplantation 8. Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure 9. Estimated creatinine clearance ≥ 45mL/min calculated by equation 10. Pulmonary function: DLCO corrected for hemoglobin > 50% and FEV1 predicted >50% based on most recent PFT results 11. Liver function acceptable per local institutional guidelines 12. KPS of ≥ 60% Stratum 3 Recipient Inclusion Criteria: 1. Age ≥18 years at the time of signing informed consent 2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements. 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Planned NMA/RIC regimen per study protocol 5. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age ≥ 18 and ≤ 40 years (≤ 35 preferred). 6. Product planned for infusion is MMUD T-cell replete PBSC allograft 7. Diagnosis of primary myelofibrosis with risk features making them eligible for HCT. Myelofibrosis secondary to essential thrombocythemia, polycythemia vera, or MDS with grade 4 fibrosis are also eligible. Patients with a myelofibrosis diagnosis require sponsor approval before enrolling. 8. Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure 9. Estimated creatinine clearance ≥ 45 mL/min calculated by equation 10. Pulmonary function: DLCO corrected for hemoglobin > 50% and FEV1 predicted >50% based on most recent PFT results 11. Liver function acceptable per local institutional guidelines 12. KPS of ≥ 60% Donor Inclusion Criteria (note: donors are not research subjects): 1. Must be unrelated to the subject and high-resolution HLA-matched at 4/8, 5/8, 6/8, or 7/8 (HLA-A, -B, -C, and -DRB1. 2. Donor must be typed at high-resolution for a minimum of HLA-A, -B, -C, -DQB1, and -DPB1. 3. Age ≥ 18 years and ≤ 40 years at the time of signing informed consent for PBSC donation. Note: donors are preferred to be ≤ 35. 4. Meet the donor registries' medical suitability requirements for PBSC donation. 5. Must undergo eligibility screening according to current Food and Drug Administration (FDA) requirements. Donors who do not meet one or more of the donor screening requirements may donate under urgent medical need. 6. Must agree to donate PBSC. 7. Must have the ability to give informed consent according to standard (non-study) informed consent according to applicable donor regulatory requirements. Recipient

Exclusion Criteria

(Strata 1, 2, and 3): 1. Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available 2. Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing 3. Subjects with a prior allogeneic transplant 4. Subjects with an autologous transplant within the past 3 months 5. Females who are breast-feeding or pregnant 6. Uncontrolled bacterial, viral, or fungal infection at the time of the transplant preparative regimen 7. Concurrent enrollment on a preventative GvHD and/or infectious disease prevention clinical trial. 8. Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant. 9. Patients who are HIV+ with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy (ART) with undetectable viral load within 6 months are eligible for this trial. Patients with well controlled HIV are eligible provided resistance panels are negative, the patient is compliant with ART, and their disease remains well controlled. Donor Exclusion Criteria: 1. Donor unwilling or unable to donate. 2. Recipient positive for HLA antibodies against a mismatched HLA in the selected donor determined by the presence of donor specific HLA antibodies (DSA) to any mismatched HLA allele/antigen at any of the following loci (HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5, -DQA1, - DQB1, -DPA1, -DPB1) with median fluorescence intensity (MFI) >3000 by microarray-based single antigen bead testing. In patients receiving red blood cell or platelet transfusions, DSA evaluation must be performed or repeated post-transfusion and prior to donor mobilization and initiation of recipient preparative regimen.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Regimen A (MAC: Busulfan and Fludarabine, PBSC HCT; Reduce Dose PTCy
Patients Receive: Patients receive: Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3 Fludarabine (150 mg/m2 total dose) IV on days -6 to -2 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
  • Drug: Busulfan
    Given IV or PO pre-transplant as part of conditioning regimen
    Other names:
    • Busulfex®
  • Drug: Fludarabine
    Given IV pre-transplant as part of conditioning regimen
    Other names:
    • Fludara®
  • Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
    Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
    Other names:
    • PBSC HSCT
    • PBSC HCT
    • PBSC Transplantation
    • PBSCT
  • Drug: Post-Transplant Cyclophosphamide
    Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours. First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
    Other names:
    • Cytoxan®
    • PTCy
  • Drug: Tacrolimus
    Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
  • Drug: Mycophenolate Mofetil
    Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
    Other names:
    • MMF
    • Cellcept®
  • Other: Patient Reported Outcomes
    Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
    Other names:
    • PRO
Experimental
Regimen B (MAC: Fludarabine and TBI, PBSC HCT; Reduce Dose PTCy
Patients receive: Fludarabine (90 mg/m2 total dose) IV on days -7 to -5 Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
  • Drug: Fludarabine
    Given IV pre-transplant as part of conditioning regimen
    Other names:
    • Fludara®
  • Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
    Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
    Other names:
    • PBSC HSCT
    • PBSC HCT
    • PBSC Transplantation
    • PBSCT
  • Drug: Post-Transplant Cyclophosphamide
    Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours. First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
    Other names:
    • Cytoxan®
    • PTCy
  • Drug: Tacrolimus
    Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
  • Drug: Mycophenolate Mofetil
    Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
    Other names:
    • MMF
    • Cellcept®
  • Other: Patient Reported Outcomes
    Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
    Other names:
    • PRO
  • Radiation: Total-body irradiation
    Administered pre-transplant as part of conditioning regimen
    Other names:
    • TBI
Experimental
Regimen C (RIC: Fludarabine and Busulfan; PBSCT HCT; Reduced Dose PTCy
Patients receive: Fludarabine (150-180 mg/m2 total dose) IV on days -6 to -2 Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
  • Drug: Busulfan
    Given IV or PO pre-transplant as part of conditioning regimen
    Other names:
    • Busulfex®
  • Drug: Fludarabine
    Given IV pre-transplant as part of conditioning regimen
    Other names:
    • Fludara®
  • Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
    Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
    Other names:
    • PBSC HSCT
    • PBSC HCT
    • PBSC Transplantation
    • PBSCT
  • Drug: Post-Transplant Cyclophosphamide
    Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours. First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
    Other names:
    • Cytoxan®
    • PTCy
  • Drug: Tacrolimus
    Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
  • Drug: Mycophenolate Mofetil
    Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
    Other names:
    • MMF
    • Cellcept®
  • Other: Patient Reported Outcomes
    Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
    Other names:
    • PRO
Experimental
Regimen D (RIC: Fludarabine and Melphalan; PBSCT HCT; Reduced Dose PTCy
Patients receive: Fludarabine (125-150 mg/m2 total dose) IV on days -7 to -3 Melphalan (100-140 mg/m2) IV on day -1 Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
  • Drug: Fludarabine
    Given IV pre-transplant as part of conditioning regimen
    Other names:
    • Fludara®
  • Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
    Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
    Other names:
    • PBSC HSCT
    • PBSC HCT
    • PBSC Transplantation
    • PBSCT
  • Drug: Post-Transplant Cyclophosphamide
    Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours. First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
    Other names:
    • Cytoxan®
    • PTCy
  • Drug: Tacrolimus
    Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
  • Drug: Mycophenolate Mofetil
    Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
    Other names:
    • MMF
    • Cellcept®
  • Other: Patient Reported Outcomes
    Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
    Other names:
    • PRO
  • Drug: Melphalan
    Given IV pre transplant as part of conditioning regimen
Experimental
Regimen E (NMA: Fludarabine, Cyclophosphamide, and TBI; PBSCT HCT; Reduced Dose PTCy
Patients receive: Fludarabine (150mg/m2 total dose) IV on days -6 to -2 Cyclophosphamide (29-50mg/kg) IV on days -6 and -5 TBI (200cGy) on day -1 Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
  • Drug: Fludarabine
    Given IV pre-transplant as part of conditioning regimen
    Other names:
    • Fludara®
  • Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
    Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
    Other names:
    • PBSC HSCT
    • PBSC HCT
    • PBSC Transplantation
    • PBSCT
  • Drug: Post-Transplant Cyclophosphamide
    Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours. First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
    Other names:
    • Cytoxan®
    • PTCy
  • Drug: Mesna
    Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.
    Other names:
    • Mesnex®
  • Drug: Tacrolimus
    Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
  • Drug: Mycophenolate Mofetil
    Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
    Other names:
    • MMF
    • Cellcept®
  • Other: Patient Reported Outcomes
    Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
    Other names:
    • PRO
  • Radiation: Total-body irradiation
    Administered pre-transplant as part of conditioning regimen
    Other names:
    • TBI
  • Drug: Cyclophosphamide
    Given IV pre-transplant as part of conditioning regimen
    Other names:
    • Cytoxan®

Recruiting Locations

Mayo Clinic Arizona
Phoenix, Arizona 85054
Contact:
Saurabh Chhabra, MD
chhabra.saurabh@mayo.edu

Honor Health
Scottsdale, Arizona 85258
Contact:
Adrienne Briggs, MD
adrienne.briggs@honorhealth.com

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Cesar Gentille Sanchez, MD
CGentille@uams.edu

City of Hope
Duarte, California 91010
Contact:
Monzr AlMalki, MD
malmalki@coh.org

Stanford University
Stanford, California 94305
Contact:
Sally Arai, MD
sara1@stanford.edu

Colorado Blood Cancer Institute at Presbyterian St. Luke's
Denver, Colorado 80218
Contact:
Marcello Rotta, MD
Marcello.Rotta@HCAHealthone.com

Mayo Clinic Jacksonville
Jacksonville, Florida 32224
Contact:
Hemant Murthy, MD
Murthy.Hemant@mayo.edu

University of Miami Sylvester Cancer Center
Miami, Florida 33136
Contact:
Antonio M Jimenez Jimenez, MD
amjimenez@miami.edu

Moffitt Cancer Center
Tampa, Florida 33612
Contact:
Farhad Khimani, MD
Farhad.Khimani@moffitt.org

Tufts University
Boston, Massachusetts 02155
Contact:
Andreas Klein, MD
aklein2@tuftsmedicalcenter.org

Dana Farber Cancer Institute
Boston, Massachusetts 02215
Contact:
Mahasweta Gooptu, MD
Mahasweta_Gooptu@DFCI.HARVARD.EDU

Karmanos Cancer Institute
Detroit, Michigan 48201
Contact:
Dipenkumar Modi, MD
modid@karmanos.org

University of Minnesota
Minneapolis, Minnesota 55455
Contact:
Mark Juckett, MD
juck0001@umn.edu

Mayo Clinic
Rochester, Minnesota 55902
Contact:
Hassan Alkhateeb, MD
alkhateeb.hassan@mayo.edu

Barnes Jewish Hospital / Washington University
Saint Louis, Missouri 63110
Contact:
Ramzi Abboud, MD
rabboud@wustl.edu

Memorial Sloan Kettering Cancer Center - Adults
New York, New York 10065
Contact:
Brian Shaffer, MD
shaffeb1@mskcc.org

University of North Carolina
Chapel Hill, North Carolina 27599
Contact:
Katarzyna Jamieson, MD
katarzyna_jamieson@med.unc.edu

Ohio State Medical Center
Columbus, Ohio 43210
Contact:
Gabriela Sanchez Petitto, MD
gabriela.sanchezpetitto@osumc.edu

Oregon Health & Science University
Portland, Oregon 97239
Contact:
Rachel J Cook, M.D.
coora@ohsu.edu

Abramson Cancer Center
Philadelphia, Pennsylvania 19104
Contact:
Shannon McCurdy, MD
Shannon.Mccurdy@pennmedicine.upenn.edu

University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania 15232
Contact:
Annie Im, MD
imap@upmc.edu

TriStar Centennial
Nashville, Tennessee 37203
Contact:
Jeremy Pantin, MD
Jeremy.Pantin@hcahealthcare.com

St. David's South Austin Medical Center
Austin, Texas 78704
Contact:
Uttam Rao, MD
Uttam.Rao@hcahealthcare.com

MD Anderson Cancer Center
Houston, Texas 77030
Contact:
Betul Oran, MD
BOran@mdanderson.org

Methodist Hospital San Antonio
San Antonio, Texas 78229
Contact:
Nosha Farhadfar, MD
Nosha.Farhadfar@hcahealthcare.com

University of Virginia Health System
Charlottesville, Virginia 22908
Contact:
Karen Ballen, M.D.

Fred Hutchinson Cancer Center
Seattle, Washington 98109
Contact:
Masumi Ueda Oshima, MD
mueda@fredhutch.org

Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Sameem Abedin, MD

More Details

NCT ID
NCT06001385
Status
Recruiting
Sponsor
Center for International Blood and Marrow Transplant Research

Study Contact

Brandan Butler, MBA
763-406-3280
bbutler@nmdp.org

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.